Aytu BioPharma (AYTU) Short Interest Ratio & Short Volume $2.20 +0.02 (+0.92%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$2.19 -0.01 (-0.45%) As of 08/22/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Aytu BioPharma Short Interest DataAytu BioPharma (AYTU) has a short interest of 585,200 shares, representing 10.84% of the float (the number of shares available for trading by the public). This marks a 11.02% increase in short interest from the previous month. The short interest ratio (days to cover) is 0.4, indicating that it would take 0.4 days of the average trading volume of 113,806 shares to cover all short positions.Current Short Interest585,200 sharesPrevious Short Interest527,100 sharesChange Vs. Previous Month+11.02%Dollar Volume Sold Short$1.43 millionShort Interest Ratio0.4 Days to CoverLast Record DateJuly 31, 2025Outstanding Shares8,980,000 sharesFloat Size5,400,000 sharesShort Percent of Float10.84%Today's Trading Volume93,694 sharesAverage Trading Volume113,806 sharesToday's Volume Vs. Average82% Short Selling Aytu BioPharma? Sign up to receive the latest short interest report for Aytu BioPharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartAYTU Short Interest Over TimeAYTU Days to Cover Over TimeAYTU Percentage of Float Shorted Over Time Aytu BioPharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/31/2025585,200 shares $1.43 million +11.0%10.8%0.4 $2.44 7/15/2025527,100 shares $1.14 million +7.1%9.8%0.4 $2.17 6/30/2025492,400 shares $1.07 million -21.2%9.1%0.4 $2.18 6/15/2025624,600 shares $1.22 million +49.9%11.6%0.5 $1.95 5/31/2025416,700 shares $741.73 thousand -43.7%7.0%0.3 $1.78 5/15/2025740,400 shares $1.92 million +445.2%12.4%0.6 $2.59 4/30/2025135,800 shares $183.33 thousand +14.4%2.3%3.7 $1.35 4/15/2025118,700 shares $123.45 thousand +1.2%2.0%3.5 $1.04 3/31/2025117,300 shares $140.76 thousand +2.3%2.0%3.4 $1.20 3/15/2025114,700 shares $138.20 thousand -4.7%1.9%3.5 $1.20 Get the Latest News and Ratings for AYTU and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Aytu BioPharma and its competitors with MarketBeat's FREE daily newsletter. 2/28/2025120,400 shares $155.32 thousand -2.8%2.0%3.5 $1.29 2/15/2025123,900 shares $171.60 thousand -3.0%2.1%3.8 $1.39 1/31/2025127,700 shares $218.37 thousand -3.0%2.2%3.7 $1.71 1/15/2025131,600 shares $215.17 thousand -4.2%2.2%3.7 $1.64 12/31/2024137,300 shares $233.41 thousand +8.3%2.3%4.1 $1.70 12/15/2024126,800 shares $182.59 thousand +7.1%2.1%3.4 $1.44 11/30/2024118,400 shares $190.62 thousand -2.0%2.0%3.4 $1.61 11/15/2024120,800 shares $190.86 thousand -37.3%2.0%4.1 $1.58 10/31/2024192,800 shares $370.18 thousand -14.4%3.2%7.8 $1.92 10/15/2024225,200 shares $515.71 thousand -14.1%3.8%10.5 $2.29 9/30/2024262,300 shares $616.41 thousand -17.0%4.4%11.9 $2.35 9/15/2024315,900 shares $815.02 thousand -2.5%5.5%18.3 $2.58 8/31/2024324,000 shares $810 thousand -0.3%5.6%16.4 $2.50 8/15/2024324,800 shares $843.18 thousand -12.8%5.6%14.6 $2.60 7/31/2024372,500 shares $987.13 thousand -6.0%6.5%16.8 $2.65 7/15/2024396,200 shares $1.12 million -3.8%6.9%19.3 $2.82 6/30/2024411,700 shares $1.20 million -9.7%7.2%19.6 $2.92 6/15/2024455,900 shares $1.30 million -1.6%7.9%21.7 $2.85 5/31/2024463,400 shares $1.46 million +10.5%8.7%24 $3.15 5/15/2024419,400 shares $1.28 million +9.5%7.8%21.7 $3.06 4/30/2024383,000 shares $1.08 million -4.8%7.2%18.5 $2.81 4/15/2024402,500 shares $1.07 million +11.5%7.5%19.8 $2.67 3/31/2024360,900 shares $1.10 million -0.2%6.7%18 $3.04 3/15/2024361,600 shares $1.04 million +3.5%6.8%16.9 $2.87 2/29/2024349,500 shares $1.01 million +4.4%6.5%14.8 $2.89 2/15/2024334,900 shares $1.04 million +6.3%6.3%14.6 $3.12 1/31/2024315,100 shares $860.22 thousand -9.6%5.9%11 $2.73 1/15/2024348,500 shares $892.16 thousand -7.4%6.5%9.1 $2.56 12/31/2023376,300 shares $1.07 million -8.2%7.0%7.9 $2.84 12/15/2023409,800 shares $1.20 million -11.7%7.7%2.5 $2.93“Sell Nvidia before earnings” (Ad)Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.See Eric’s full analysis and get all 7 free trade ideas here 11/30/2023464,000 shares $1.06 million -23.1%8.7%2.8 $2.29 11/15/2023603,000 shares $1.38 million -4.7%11.3%3.7 $2.29 10/31/2023632,800 shares $1.73 million -14.9%12.1%4 $2.73 10/15/2023743,200 shares $2.22 million +112.6%14.2%4.8 $2.99 9/30/2023349,600 shares $943.92 thousand +5.8%9.8%2.4 $2.70 9/15/2023330,300 shares $535.09 thousand -6.4%9.3%11.2 $1.62 8/31/2023352,800 shares $599.76 thousand +12.0%9.9%8.9 $1.70 8/15/2023314,900 shares $588.86 thousand -1.7%8.8%6.8 $1.87 7/31/2023320,200 shares $579.56 thousand -6.2%8.9%5.6 $1.81 7/15/2023341,500 shares $638.61 thousand -8.8%9.5%4.1 $1.87 6/30/2023374,600 shares $599.36 thousand -39.3%10.5%4.4 $1.60 6/15/2023616,700 shares $1.14 million +3.3%17.2%7.4 $1.85 5/31/2023596,800 shares $996.66 thousand -0.1%16.6%7.4 $1.67 5/15/2023597,300 shares $1.07 million +23.6%16.6%7.2 $1.79 4/30/2023483,200 shares $1.14 million -9.6%14.3%6.2 $2.35 4/15/2023534,300 shares $1.36 million +4.1%15.8%9.8 $2.55 3/31/2023513,200 shares $1.15 million +3.1%15.2%7.9 $2.24 3/15/2023497,600 shares $1.17 million +0.8%14.7%6.2 $2.35 2/28/2023493,900 shares $1.31 million +12.3%15.3%6.4 $2.66 2/15/2023440,000 shares $1.31 million +8.7%13.7%5.7 $2.98 1/31/2023404,700 shares $1.34 million +16.9%12.5%5.3 $3.30 1/15/2023346,300 shares $1.20 million +99.3%10.8%4.8 $3.47 12/30/2022173,800 shares $32.85 thousand -93.9%N/A2.8 $0.19 12/15/20222,830,000 shares $602.51 thousand -6.3%N/A2.6 $0.21 11/30/20223,020,000 shares $619.40 thousand +24.8%N/A3 $0.21 11/15/20222,420,000 shares $473.11 thousand +36.0%N/A2.3 $0.20 10/31/20221,780,000 shares $291.92 thousand No ChangeN/A1.3 $0.16 10/15/20221,780,000 shares $295.66 thousand +17.9%N/A1.3 $0.17 9/30/20221,510,000 shares $279.35 thousand +42.5%N/A1.1 $0.19 9/15/20221,060,000 shares $231.08 thousand -8.6%N/A0.8 $0.22 8/31/20221,160,000 shares $258.10 thousand -22.2%N/A1 $0.22 8/15/20221,490,000 shares $427.63 thousand +29.6%N/A1.5 $0.29 7/31/20221,150,000 shares $598 thousand -0.9%N/A1.5 $0.52 7/15/20221,160,000 shares $694.84 thousand -12.1%N/A2 $0.60 6/30/20221,320,000 shares $910.80 thousand No ChangeN/A1.1 $0.69 6/15/20221,320,000 shares $646.80 thousand +11.9%N/A1.3 $0.49 5/31/20221,180,000 shares $644.28 thousand -15.1%N/A1.2 $0.55 5/15/20221,390,000 shares $717.52 thousand -17.3%N/A1.4 $0.52 4/30/20221,680,000 shares $1.08 million +7.7%N/A1.7 $0.65 4/15/20221,560,000 shares $1.46 million -6.0%N/A1.7 $0.93 3/31/20221,660,000 shares $1.79 million -11.7%N/A8.7 $1.08 3/15/20221,880,000 shares $2.05 million +2.2%N/A7.6 $1.09 2/28/20221,840,000 shares $2.32 million +0.6%N/A4.7 $1.26 2/15/20221,830,000 shares $2.43 million +15.8%N/A4.2 $1.33 1/31/20221,580,000 shares $2.07 million -8.7%N/A3.3 $1.31 1/15/20221,730,000 shares $2.34 million +13.8%N/A3.5 $1.35 12/31/20211,520,000 shares $2.05 million -15.1%N/A3.1 $1.35 12/15/20211,790,000 shares $2.83 million +1.7%N/A3.7 $1.58 11/30/20211,760,000 shares $3.45 million +8.6%N/A3.9 $1.96 11/15/20211,620,000 shares $3.97 million -16.1%N/A4.3 $2.45“Sell Nvidia before earnings” (Ad)Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.See Eric’s full analysis and get all 7 free trade ideas here 10/29/20211,930,000 shares $4.81 million +31.3%7.8%5.6 $2.49 10/15/20211,470,000 shares $3.90 million -31.0%5.9%4.2 $2.65 9/30/20212,130,000 shares $6.13 million -4.9%8.7%5.5 $2.88 9/15/20212,240,000 shares $6.81 million +18.5%10.2%4.4 $3.04 8/31/20211,890,000 shares $7.18 million -6.0%8.6%2.4 $3.80 8/13/20212,010,000 shares $6.95 million -8.6%9.1%2.2 $3.46 7/30/20212,200,000 shares $8.73 million +12.8%10.0%2.3 $3.97 7/15/20211,950,000 shares $8.39 million +21.9%8.9%2.1 $4.30 6/30/20211,600,000 shares $8.02 million -37.5%7.3%1.7 $5.01 6/15/20212,560,000 shares $13.21 million +2.8%11.7%3 $5.16 5/28/20212,490,000 shares $12.65 million +7.3%11.5%3.4 $5.08 5/14/20212,320,000 shares $12.11 million +11.5%N/A3.6 $5.22 4/30/20212,080,000 shares $13.96 million +12.4%N/A3 $6.71 4/15/20211,850,000 shares $12.62 million +25.0%N/A2.7 $6.82 3/31/20211,480,000 shares $10.98 million +148.2%N/A2 $7.42 3/15/2021596,400 shares $5.12 million +60.1%3.7%0.8 $8.59 2/26/2021372,600 shares $2.94 million +9.4%2.3%0.4 $7.90 2/12/2021340,700 shares $2.98 million +1.8%2.1%0.4 $8.74 1/29/2021334,800 shares $2.44 million -26.6%2.1%0.4 $7.29 1/15/2021456,000 shares $3.37 million -37.9%2.9%0.6 $7.39 12/31/2020734,600 shares $4.44 million -8.4%4.9%1 $6.04 12/15/2020801,800 shares $4.80 million -91.7%5.3%1.2 $5.99 11/30/20209,710,000 shares $8.93 million +7.3%86.3%29.2 $0.92 11/15/20209,050,000 shares $8.77 million -10.1%N/A2.8 $0.97 10/30/202010,070,000 shares $9.87 million -9.9%N/A3.1 $0.98 10/15/202011,180,000 shares $11.85 million -2.4%N/A3.1 $1.06 9/30/202011,450,000 shares $13.63 million +129.0%N/A2.6 $1.19 9/15/20205,000,000 shares $5.90 million -6.2%N/A0.9 $1.18 8/31/20205,330,000 shares $5.65 million -12.1%N/A0.9 $1.06 AYTU Short Interest - Frequently Asked Questions What is Aytu BioPharma's current short interest? Short interest is the volume of Aytu BioPharma shares that have been sold short but have not yet been closed out or covered. As of July 31st, investors have sold 585,200 shares of AYTU short. 10.84% of Aytu BioPharma's shares are currently sold short. Learn More on Aytu BioPharma's current short interest. What is a good short interest percentage for Aytu BioPharma? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 10.84% of Aytu BioPharma's floating shares are currently sold short. Is Aytu BioPharma's short interest increasing or decreasing? Aytu BioPharma saw a increase in short interest during the month of July. As of July 31st, there was short interest totaling 585,200 shares, an increase of 11.0% from the previous total of 527,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Aytu BioPharma's float size? Aytu BioPharma currently has issued a total of 8,980,000 shares. Some of Aytu BioPharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Aytu BioPharma currently has a public float of 5,400,000 shares. How does Aytu BioPharma's short interest compare to its competitors? 10.84% of Aytu BioPharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Aytu BioPharma: ESSA Pharma Inc. (2.05%), Vaxart, Inc. (3.62%), Oncolytics Biotech Inc. (2.51%), Alto Neuroscience, Inc. (10.00%), Entera Bio Ltd. (0.14%), Elutia Inc. (0.09%), Acumen Pharmaceuticals, Inc. (2.98%), Surrozen, Inc. (1.73%), Cardiol Therapeutics Inc. (2.24%), BeyondSpring Inc. (7.37%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.87 billion), Invesco QQQ ($30.12 billion), iShares Russell 2000 ETF ($19.85 billion), iShares 20+ Year Treasury Bond ETF ($10.34 billion), Strategy Inc ($8.98 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($7.61 billion), SPDR S&P Biotech ETF ($6.81 billion), Invesco S&P 500 Equal Weight ETF ($6.14 billion), Palo Alto Networks, Inc. ($5.97 billion), and Super Micro Computer, Inc. ($5.28 billion). View all of the most shorted stocks. What does it mean to sell short Aytu BioPharma stock? Short selling AYTU is an investing strategy that aims to generate trading profit from Aytu BioPharma as its price is falling. AYTU shares are trading up $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Aytu BioPharma? A short squeeze for Aytu BioPharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of AYTU, which in turn drives the price of the stock up even further. How often is Aytu BioPharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including AYTU, twice per month. The most recent reporting period available is July, 31 2025. More Short Interest Resources from MarketBeat Related Companies EPIX Short Interest Data VXRT Short Interest Data ONCY Short Interest Data ANRO Short Interest Data ENTX Short Interest Data ELUT Short Interest Data ABOS Short Interest Data SRZN Short Interest Data CRDL Short Interest Data BYSI Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:AYTU) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredCould This Be the End of Retirement Worries?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aytu BioPharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aytu BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access